HIV-1 TAT 48-60
目录号 : GC34235
HIV-1TAT(48-60)是源自人免疫缺陷病毒(HIV)-1蛋白残基48-60，可渗透细胞的多肽。它已被用于以不中断的方式将外源性大分子递送到细胞中。
Cas No.:220408-24-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
HIV-1 TAT (48-60) is a cell-penetrating peptide derived from the human immunodeficient virus (HIV)-1 Tat protein residue 48-60. It has been used to deliver exogenous macromolecules into cells in a non-disruptive way.
Studies show that exogenous Tat protein is able to translocate through the plasma membrane and to reach the nucleus to transactivate the viral genome. The HIV-1 TAT (48-60) peptide, which contains the basic domain of the full length peptide only, retains the full translocation activity and even appears more efficient in terms of nuclear localization when compared with the other active peptides at the standard dose of 1 mM[1]. Cell-penetrating peptides are regarded as promising vectors for intracellular delivery of large, hydrophilic molecules. An apparently endocytotic uptake of HIV-1 TAT (48-60) is observed by confocal laser scanning microscopy[2]. HIV-1 TAT (48-60) induces the formation of rodlike, presumably inverted micelles in DMPC, which may represent intermediates during the translocation across eukaryotic membranes[3].
[1]. Vivès E, et al. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem. 1997 Jun 20;272(25):16010-7. [2]. Thorén PE, et al. Uptake of analogs of penetratin, Tat(48-60) and oligoarginine in live cells. Biochem Biophys Res Commun. 2003 Jul 18;307(1):100-7. [3]. Afonin S, et al. The cell-penetrating peptide TAT(48-60) induces a non-lamellar phase in DMPC membranes. Chemphyschem. 2006 Oct 13;7(10):2134-42.
Cell experiment: | HeLa cells are incubated for 24 h with increasing concentrations (0-100 μM) of HIV-1 TAT (48-60). Cell viability is measured following a standard MTT assay procedure and is expressed as the ratio of A570 of cells treated with peptide over control sample[1]. |
References: [1]. Vivès E, et al. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem. 1997 Jun 20;272(25):16010-7. | |
| Cas No. | 220408-24-2 | SDF | |
| Canonical SMILES | Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Pro-Pro-Gln | ||
| 分子式 | C70H131N35O16 | 分子量 | 1719 |
| 溶解度 | DMSO : ≥ 100 mg/mL (58.17 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.5817 mL | 2.9087 mL | 5.8173 mL |
| 5 mM | 0.1163 mL | 0.5817 mL | 1.1635 mL |
| 10 mM | 0.0582 mL | 0.2909 mL | 0.5817 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet